menu

Metastatic Melanoma: Solving Clinical Dilemmas in Frontline ICI Treatment

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Metastatic Melanoma: Solving Clinical Dilemmas in Frontline ICI Treatment

3 episodes
0.50 program credits
37m
MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Program Post-Test
Program Post-Test Completed
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    This program focuses on frontline therapies for patients with metastatic melanoma. It discusses strategies for sequencing immune checkpoint inhibitors (ICIs) and patient characteristics that guide choice of treatment. The program includes topics such as the scientific rationale driving research, efficacy and safety data from recent pivotal clinical trials, and clinical management dilemmas. This program provides busy clinicians with an opportunity to listen to experts discuss critical takeaways from research studies and implications for current practice, such as treatment selection and effective management of treatment-related adverse events (AEs). Learners will be able to better understand optimal treatment sequencing while becoming more aware of clinical challenges associated with immunotherapy, such as toxicity management as well as difficult patient scenarios.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team including medical oncologists, oncology nurses, and oncology pharmacists,as well as other clinicians involved in the management of patients with metastatic melanoma.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Review the risks and benefits of dual immune checkpoint inhibition and identify patient and disease characteristics that may impact the choice of therapy 
    • Use data to determine optimal treatment sequencing for BRAF-mutated, metastatic melanoma
    • Review clinical challenges surrounding the use of immune checkpoint inhibitors in metastatic melanoma
  • Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
     
    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. 

  • Faculty Disclosure of Commercial Relationships

    Disclosure Policy
    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Jason J. Luke, MD, FACP, chair for this educational event receives research funds from AbbVie, Astellas, AstraZeneca, Bristol-Myers Squibb, Corvus, Day One, EMD Serono, Fstar, Genmab, Hot Spot, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, Next Cure, Numab, Palleon, Pfizer, Replimmune, Rubius, Servier, Scholar Rock, Synlogic, Takeda, Trishula, Tizona, and Xencor; receives consulting fees from (no stock) 7 Hills, Affivant, BioCytics, Bright Peak, Exo, Fstar, Inzen, RefleXion, Xilio (stock) Actym, Alphamab Oncology, Arch Oncology, Duke Street Bio, Kanaph, Mavu, NeoTx, Onc.AI, OncoNano, physIQ, Pyxis, Saros, STipe, and Tempest. 

    Elizabeth Buchbinder, MD, faculty for this educational event receives research funds from Genentech, BMS, Merck, and Partners therapeutics; and receives consulting fees from Iovance, Merck, Sanofi, Xilio, Novartis, Instilbio, and Nektar. 

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Megan Reimann, PharmD, BCOP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by an independent educational grant from Bristol Myers Squibb.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 6/15/2023 through 7/14/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:
    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule24 Jun 2024